The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | S | Sensory organs | |
| 2 | S01 | Ophthalmologicals | |
| 3 | S01B | Antiinflammatory agents | |
| 4 | S01BC | Antiinflammatory agents, non-steroids | |
| 5 | S01BC11 |
| Active Ingredient | Description | |
|---|---|---|
| Bromfenac |
Bromfenac is a topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. The most commonly reported adverse reactions in 3 to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia and vision blurred. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| PROLENSA Ophthalmic solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| YELLOX Eye drops, solution | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
